Featured
Featured Videos
Bioprocessing in Boston: GEN Reports Live from BPI 2024
- Seres Therapeutics, developer of the first microbiome therapy platform
- Ring Therapeutics, a developer of gene therapies based on its commensal virome platform
- Cellarity, which aims to design medicines targeting the full cellular and molecular complexity of disease as opposed to a single molecular target
- Abiologics, a developer of programmable medicines combining generative artificial intelligence and high throughput chemical protein synthesis (it emerged from stealth mode in July)
- Cygnal Therapeutics, now part of Sonata Therapeutics, whose Network Medicines™ reprogram diseased cells to become “coordinators of cure” by releasing a defined array of signals designed to precisely coordinate multicellular networks to drive disease resolution
Avak Kahvejian, PhD, Recounts His Journey from Sequencing Pioneer to Flagship General Partner on “Close to the Edge”
Spatial biology reveals the cosmos within, much like astronomy reveals the cosmos without. Both disciplines generate imagery that relies on “false color” to reveal structures and spatial relationships that would otherwise remain unseen. (Notice how this month’s cover, which highlights spatial biology, has a cosmological aspect.) As the newer discipline, spatial biology has some catching up to do. To see how it’s progressing, see this month’s A-List, which ranks the top 10 spatial biology companies. The list was compiled after some recent M&A activity, including Bruker’s acquisition of NanoString Technologies, the implications of which are discussed by Bruker executives in an interview with Julianna LeMieux, PhD, GEN’s deputy editor in chief. Just one of these implications is the evolution of a whole new science, one that describes cellular organization in terms of molecular signals and biomechanical forces—rather like astronomy describes the universe’s large-scale structures in terms of gravitational interactions.